A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation

dc.contributor.authorMoncunill Massaguer, Cristina
dc.contributor.authorSaura-Esteller, José
dc.contributor.authorPérez-Perarnau, Alba
dc.contributor.authorPalmeri, Claudia Mariela
dc.contributor.authorNúñez-Vázquez, Sonia
dc.contributor.authorCosialls Castel, Ana Mª
dc.contributor.authorGonzález Gironés, Diana M.
dc.contributor.authorPomares, Helena
dc.contributor.authorKorwitz, Anne
dc.contributor.authorPreciado Gallego, Sara
dc.contributor.authorAlbericio Palomera, Fernando
dc.contributor.authorLavilla Grífols, Rodolfo
dc.contributor.authorPons i Irazazábal, Gabriel
dc.contributor.authorLanger, Thomas
dc.contributor.authorIglesias i Serret, Daniel
dc.contributor.authorGil i Santano, Joan
dc.date.accessioned2016-03-30T15:13:02Z
dc.date.available2016-03-30T15:13:02Z
dc.date.issued2015-10-19
dc.date.updated2016-03-30T15:13:07Z
dc.description.abstractWe previously described diaryl trifluorothiazoline compound 1a (hereafter referred to as fluorizoline) as a first-in-class small molecule that induces p53-independent apoptosis in a wide range of tumor cell lines. Fluorizoline directly binds to prohibitin 1 and 2 (PHBs), two proteins involved in the regulation of several cellular processes, including apoptosis. Here we demonstrate that fluorizoline-induced apoptosis is mediated by PHBs, as cells depleted of these proteins are highly resistant to fluorizoline treatment. In addition, BAX and BAK are necessary for fluorizoline-induced cytotoxic effects, thereby proving that apoptosis occurs through the intrinsic pathway. Expression analysis revealed that fluorizoline induced the upregulation of Noxa and Bim mRNA levels, which was not observed in PHB-depleted MEFs. Finally, Noxa-/-/Bim-/- MEFs and NOXA-downregulated HeLa cells were resistant to fluorizoline-induced apoptosis. All together, these findings show that fluorizoline requires PHBs to execute the mitochondrial apoptotic pathway.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec656815
dc.identifier.issn1949-2553
dc.identifier.pmid26497683
dc.identifier.urihttps://hdl.handle.net/2445/96766
dc.language.isoeng
dc.publisherImpact Journals
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.18632/oncotarget.6154
dc.relation.ispartofOncotarget, 2015, vol. 6, num. 39, p. 41750-41765
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/233078/EU//MITOSCAFFOLD
dc.relation.urihttp://dx.doi.org/10.18632/oncotarget.6154
dc.rightscc-by (c) Moncunill-Massaguer,Cristina et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationCàncer
dc.subject.classificationApoptosi
dc.subject.classificationMitocondris
dc.subject.otherCancer
dc.subject.otherApoptosis
dc.subject.otherMitochondria
dc.titleA novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
656815.pdf
Mida:
2.38 MB
Format:
Adobe Portable Document Format